A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2.
about
Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotypeTreatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7.Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide.Oral vaccination: where we are?The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide.Nitric oxide inhibits Shiga-toxin synthesis by enterohemorrhagic Escherichia coliA potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo.Interaction between Shiga toxin and monoclonal antibodies: binding characteristics and in vitro neutralizing abilities.Needle-free vaccine delivery.Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans.Plant-made immunogens and effective delivery strategies.Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.
P2860
Q28087714-424270F2-6D14-4BD7-BE93-4C998F0B2146Q33399468-49A730E9-CCA9-48E8-BE69-4B7B26D2B721Q33404149-84D56DB2-8916-4CEC-B638-5D343182A90CQ33965188-F3C7502D-B343-4981-8006-77BE5109D2D1Q34290908-7B88E023-2CDA-424A-9BC8-A7CFEA0C1903Q34660422-ABA83EFC-BC79-4EB9-B01C-341626259F6CQ35220377-C2770288-62AF-4E22-9BF6-9C068E6E36BAQ35840558-F97FA896-0120-4E7D-86FF-8E4B4E112317Q35931774-58F6B97F-1308-41A1-85DD-75DFB5276FC3Q36329665-42FB5172-A611-46EB-A0F6-7ED1858F1156Q36945838-F9B369AE-24F9-48F6-9875-A64326A934E9Q37077633-351203B3-8A48-43C0-91E0-06AA3DB603F4Q37776713-A50D3B31-7757-445B-83C8-8286946DB8F1Q53696162-25A6751E-D12D-4CA8-B927-D0A2C7FE196BQ54454112-FA142C98-800F-46F6-87CC-C43634616B7D
P2860
A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A plant-based oral vaccine to ...... ication by Shiga toxin type 2.
@ast
A plant-based oral vaccine to ...... ication by Shiga toxin type 2.
@en
type
label
A plant-based oral vaccine to ...... ication by Shiga toxin type 2.
@ast
A plant-based oral vaccine to ...... ication by Shiga toxin type 2.
@en
prefLabel
A plant-based oral vaccine to ...... ication by Shiga toxin type 2.
@ast
A plant-based oral vaccine to ...... ication by Shiga toxin type 2.
@en
P2093
P2860
P356
P1476
A plant-based oral vaccine to ...... ication by Shiga toxin type 2.
@en
P2093
Louise D Teel
Nicole A Judge
Sharon X Wen
P2860
P304
P356
10.1073/PNAS.0510843103
P407
P577
2006-04-25T00:00:00Z